A&D Pharma, the biggest pharmaceutical company on the domestic market, stepped into the black in 2009, when it posted 19 million euros in net profit after two loss-making years. The turnover was up 3% to 514 million euros. The pharmaceutical market in Romania shrank by 1.5% to 1.92 billion euros.
The net profit was the result of steps taken to make the local operations efficient and of the enforcement of a restructuring programme that generated 6 million euros in savings, the company officials say.
At the same time, A&D Pharma announced the completion of the takeover of
Ozone Laboratories' operations in Poland, Czech Republic, Hungary, Slovenia and Bulgaria in a deal put at 20-23 million euros.
The list of 2010-2011 development goals of A&D Pharma also includes growth by greenfield investments of its newest business - the medical service division Anima, with the company specifying it had an untapped indebtedness capacity of 60 million euros.
A&D Pharma, the biggest pharmaceutical company on the domestic market, stepped into the black in 2009, when it posted 19 million euros in net profit after two loss-making years. The turnover was up 3% to 514 million euros. The pharmaceutical market in Romania shrank by 1.5% to 1.92 billion euros.
The net profit was the result of steps taken to make the local operations efficient and of the enforcement of a restructuring programme that generated 6 million euros in savings, the company officials say.
At the same time, A&D Pharma announced the completion of the takeover of
Ozone Laboratories' operations in Poland, Czech Republic, Hungary, Slovenia and Bulgaria in a deal put at 20-23 million euros.
The list of 2010-2011 development goals of A&D Pharma also includes growth by greenfield investments of its newest business - the medical service division Anima, with the company specifying
